Quote this publication Share Print

RYDAPT (midostaurin), tyrosine kinase inhibitor

ONCOLOGY - New medicinal product
Opinions on drugs - Posted on Feb 22 2019

Reason for request

Inclusion

Low clinical benefit in the treatment of aggressive systemic mastocytosis (ASM), systemic mastocytosis associated with a second malignant blood disorder (SM-SBD) or mast cell leukaemia (MCL), but no demonstrated clinical advantage in the therapeutic strategy.

 

  • RYDAPT has been granted a marketing authorisation for the treatment of adults presenting with aggressive systemic mastocytosis (ASM), systemic mastocytosis associated with a second malignant blood disorder (SM-SBD), or mast cell leukaemia (MCL), in monotherapy.

  • Efficacy data are limited to one non-comparative phase II study showing an overall response rate of nearly 60%, though lacking any conclusive data showing an increase in overall survival or quality of life.

 

 


Actual benefit

Faible

-


Improvement in actual benefit

V (absence)

-


Ce produit a fait l'objet d'un avis d'efficience rendu par la commission évaluation économique et santé publique le 10 avril 2018.

See also